<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Endometriosis: Management of ovarian endometriomas</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Endometriosis: Management of ovarian endometriomas</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Endometriosis: Management of ovarian endometriomas</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara S Levy, MD, FACOG</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Howard T Sharp, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>An ovarian endometrioma is a cystic mass arising from ectopic endometrial tissue within the ovary. It contains thick, brown, tar-like fluid, which may be referred to as a "chocolate cyst." Endometriomas are often densely adherent to surrounding structures, such as the peritoneum, fallopian tubes, uterus, and bowel. This topic will review management of ovarian endometriomas.</p><p>Information on adnexal masses and the clinical diagnosis and management of endometriosis is discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/83704.html" rel="external">"Approach to the patient with an adnexal mass"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7384.html" rel="external">"Endometriosis in adults: Pathogenesis, epidemiology, and clinical impact"</a>.)</p><p></p><p>In this topic, when discussing study results, we will use the terms "women" or "patients" as they are used in the studies presented. However, we encourage the reader to consider the specific counseling and treatment needs of transgender and gender diverse individuals.</p><p class="headingAnchor" id="H363548427"><span class="h1">BASELINE EVALUATION</span><span class="headingEndMark"> — </span>The baseline evaluation for individuals with suspected endometriomas includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Assessment of symptoms</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pelvic imaging, typically with transvaginal ultrasound</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assessment of the risk of malignancy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation of the patient's ovarian reserve</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Planning for future fertility</p><p></p><p class="headingAnchor" id="H1161812914"><span class="h2">Assess symptoms</span><span class="headingEndMark"> — </span>Endometriomas can be asymptomatic or cause symptoms of pain, dyspareunia, and/or mass effect. Endometriomas causing bothersome symptoms that interfere with routine function are removed for symptom relief [<a href="#rid1">1-4</a>].</p><p class="headingAnchor" id="H56270874"><span class="h2">Perform imaging</span><span class="headingEndMark"> — </span>Imaging studies are performed to confirm a likely endometrioma, exclude findings suggestive of malignancy, and assess for change over time. While definitive diagnosis of an endometrioma requires histologic evaluation of a surgical specimen, imaging findings have high sensitivity and specificity for detecting an endometrioma. (See  <a class="medical medical_review" href="/z/d/html/134970.html" rel="external">"Endometriosis: Clinical features, evaluation, and diagnosis", section on 'Imaging'</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ultrasound</strong> <strong>imaging</strong> – Ultrasound is typically the first-line imaging study for evaluating an adnexal mass  (<a class="graphic graphic_diagnosticimage graphicRef77161 graphicRef52113" href="/z/d/graphic/77161.html" rel="external">image 1A-B</a>) [<a href="#rid5">5</a>]; the sensitivity and specificity are greater than 90 percent for diagnosing an endometrioma [<a href="#rid6">6,7</a>]. Individuals with an indeterminate adnexal mass may benefit from repeat interval imaging (eg, hemorrhagic cyst) or magnetic resonance imaging (MRI) for further delineation (eg, concern for malignancy) [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/83704.html" rel="external">"Approach to the patient with an adnexal mass", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1">Findings suggestive of an endometrioma include an avascular, thick-walled cystic mass that contains material with a homogenous low-level echo pattern (ie, ground-glass appearance)  (<a class="graphic graphic_diagnosticimage graphicRef77161 graphicRef52113 graphicRef109394" href="/z/d/graphic/77161.html" rel="external">image 1A-C</a>) [<a href="#rid5">5,8</a>]. The lesion may be uni- or multilocular; multilocular lesions can have varying levels of echogenicity. Septations should be smooth and there should be no solid elements. Cyst size is measured in three orthogonal planes [<a href="#rid9">9</a>]. Serial images can assess subsequent changes in size or appearance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Magnetic resonance imaging (MRI)</strong> – MRI can be useful if the initial ultrasound findings are indeterminate for endometrioma or to assist with preoperative planning [<a href="#rid6">6,7,10</a>]. The number of adnexal lesions that remains with an indeterminate diagnosis drops from 20 to 25 percent with ultrasound to 5 to 7 percent with MRI [<a href="#rid11">11-17</a>].</p><p></p><p class="headingAnchor" id="H1633829575"><span class="h2">Assess risk for malignancy</span><span class="headingEndMark"> — </span>While the overall risk of malignancy within an endometrioma is low, typically less than 0.8 percent, risk of malignancy is increased with larger lesions (&gt;9 cm) and increasing patient age (&gt;45 years) [<a href="#rid18">18</a>]. Endometriosis of the ovary is also associated with a small increased risk of transformation to ovarian cancer; the most common histologies are clear cell and endometrioid [<a href="#rid19">19-21</a>]. For these reasons, endometriomas are removed if they have an atypical appearance on imaging studies, other concerning features (eg, enlarging size, nodularity), or occur in patients of older age [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/7384.html" rel="external">"Endometriosis in adults: Pathogenesis, epidemiology, and clinical impact", section on 'Ovarian cancer risk'</a>.)</p><p>Serum CA 125 level is generally not helpful in assessing for possible malignancy because the level may be increased with benign endometriomas [<a href="#rid23">23,24</a>]. However, CA 125 levels over 200 units/mL has been used as a criterion for specialist referral and evaluation for possible malignancy [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/z/d/html/16557.html" rel="external">"Adnexal mass: Role of serum biomarkers in diagnosing epithelial carcinoma of the ovary, fallopian tube, or peritoneum"</a> and  <a class="medical medical_review" href="/z/d/html/16557.html" rel="external">"Adnexal mass: Role of serum biomarkers in diagnosing epithelial carcinoma of the ovary, fallopian tube, or peritoneum", section on 'Biomarkers'</a>.) </p><p class="headingAnchor" id="H6362327"><span class="h2">Assess fertility and desire for pregnancy</span><span class="headingEndMark"> — </span>Excision of endometriomas improves spontaneous pregnancy rates in subfertile individuals but has no impact when advanced reproductive technologies such as in vitro fertilization (IVF) are employed [<a href="#rid26">26</a>]. Endometrioma resection has not been shown to improve IVF/intracytoplasmic sperm injection outcomes and therefore is not advised for this indication [<a href="#rid4">4,27-29</a>]. Patients planning IVF or intracytoplasmic sperm injection should consider endometrioma resection only if they are having bothersome symptoms (eg, pain or mass), to exclude malignancy, or if the size and/or position of the endometrioma would preclude follicle aspiration during a planned future IVF cycle [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/7408.html" rel="external">"Endometriosis: Treatment of infertility in females"</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span>In one study of women with subfertility and endometriomas, excision of the endometrioma was associated with an increased spontaneous pregnancy rate compared with women who had cyst wall ablation only [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Conception and pregnancy rates are <strong>not</strong> improved when endometriomas are treated with hormonal treatments such as <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a> or gonadotropin-releasing hormone (GnRH) agonists, although cyst size may be reduced [<a href="#rid30">30,31</a>]. (See <a class="local">'Active surveillance'</a> below.)</p><p></p><p class="headingAnchor" id="H238460076"><span class="h1">CONSIDER IMPORTANCE OF OVARIAN RESERVE</span><span class="headingEndMark"> — </span>Ovarian reserve, as measured by serum anti-müllerian hormone (AMH), is decreased in patients with endometriomas &gt;3 cm in diameter and further decreased if the endometrioma is surgically removed [<a href="#rid32">32</a>]. While AMH level does not predict the probability of natural conception, it does predict live birth following in vitro fertilization (IVF). Therefore, the decision to proceed with ovarian surgery requires a careful discussion with the patient regarding the impact on ovarian function. AMH levels are only one marker of ovarian reserve and must be assessed within the entire clinical context; more information on ovarian reserve is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5445.html" rel="external">"Female infertility: Evaluation", section on 'Assessment of ovarian reserve'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of endometrioma</strong> – Endometrioma has been associated with reduced AMH levels and greater AMH decline over time [<a href="#rid33">33,34</a>]. In a study comparing AMH levels in 40 patients with endometrioma &gt;3 cm with 40 age-matched control individuals without endometriomas, those with endometriomas had lower median AMH levels at study recruitment (2.83 versus 4.42 ng/mL) and greater AMH decline over six months (26 versus 7 percent) [<a href="#rid34">34</a>]. Although the endometrioma may reduce AMH levels and the number of follicles recruited in the ovary by exogenous follicle-stimulating hormone (FSH) stimulation, endometriomas do not appear to negatively impact pregnancy or live birth rates after IVF [<a href="#rid35">35-37</a>]. However, the reduction in follicle count may negatively impact individuals undergoing IVF with the goal of preserving oocytes or embryos for possible future use.  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of endometrioma surgery (cystectomy)</strong> – Ovarian surgery to remove the endometrioma (ie, cystectomy) is associated with reduced ovarian reserve as assessed by AMH levels but not by antral follicle count (AFC) [<a href="#rid38">38-40</a>]. It is unclear if AMH falls because of surgical trauma to the ovary or removal of normal ovarian tissue and follicles.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cystectomy and AMH</strong> – A meta-analysis of 14 prospective studies comparing pre- and postoperative AMH and AFC levels in 650 females who underwent endometrioma resection (cystectomy) reported reductions in weighted mean AMH of 44, 35, and 54 percent at early (one to six week), intermediate (two to six months), and late (nine to eighteen months) postoperative time intervals, respectively [<a href="#rid38">38</a>]. By contrast, weighted mean AFC levels were similar pre- and postoperatively. Other studies have reported bilateral cystectomy for endometriomas may result in a greater reduction in AMH levels than unilateral ovarian cystectomy [<a href="#rid41">41,42</a>]. While AMH does not predict the probability of natural conception, it does predict the likelihood of live birth following IVF [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Repeat surgeries and AMH</strong> – A prospective study that assessed ovarian function reported a greater loss of ovarian tissue and antral follicles in the females undergoing repeat surgery compared with those undergoing primary endometrioma resection [<a href="#rid43">43</a>]. The authors cautioned against repeat surgical intervention for endometriomas.</p><p></p><p class="headingAnchor" id="H2961519357"><span class="h1">TREATMENT GOALS AND OPTIONS</span><span class="headingEndMark"> — </span>Treatment options include active surveillance with serial imaging and surgical excision (cystectomy or oophorectomy). Medical therapy and cyst sclerotherapy are not advised. (See <a class="local">'Lack of benefit'</a> below.)</p><p class="headingAnchor" id="H1986045151"><span class="h2">Select treatment approach</span><span class="headingEndMark"> — </span>The goals of endometrioma treatment are to relieve symptoms (eg, pain or mass), exclude malignancy, and improve subfertility (if assisted reproductive technology is not being pursued), all while preserving ovarian function. (See <a class="local">'Baseline evaluation'</a> above.)</p><p>The main treatment options include active surveillance with serial imaging or surgical removal with cystectomy or oophorectomy  (<a class="graphic graphic_algorithm graphicRef135005" href="/z/d/graphic/135005.html" rel="external">algorithm 1</a>). The relative priority of each of the treatment goals above informs treatment selection.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Active surveillance</strong> – In the absence of symptoms or concerning findings, observation with serial imaging is preferred as it avoids the risks of surgery and the potential negative impact of surgery on ovarian reserve. (See <a class="local">'Active surveillance'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical treatment</strong> – When surgery is elected, the goals are to relieve symptoms (eg, pain or mass), exclude malignancy, and improve subfertility with minimizing negative impact on ovarian function. Surgical options include cystectomy (ie, removal of the endometrioma only with preservation of the ovary) or oophorectomy (ie, removal of the ovary with the intact cyst within it). When cost is included in the decision-making process, one group reported that salpingo-oophorectomy may be preferred to cystectomy [<a href="#rid44">44</a>]. (See <a class="local">'Surgery'</a> below.)</p><p></p><p>Sclerotherapy and medication management are not advised as they are ineffective. (See <a class="local">'Lack of benefit'</a> below.)</p><p class="headingAnchor" id="H1543940550"><span class="h2">Active surveillance</span><span class="headingEndMark"> — </span>Active surveillance employs serial ultrasounds to confirm findings consistent with an endometrioma and cyst stability  (<a class="graphic graphic_algorithm graphicRef135005" href="/z/d/graphic/135005.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection, benefits, and risks</strong> – Active surveillance with serial imaging is appropriate for most patients and includes those who are asymptomatic, who have small lesions (&lt;5 cm), are at low risk for malignancy based on clinical factors and imaging findings, and who prioritize their existing ovarian function [<a href="#rid3">3</a>]. (See <a class="local">'Assess risk for malignancy'</a> above and <a class="local">'Assess fertility and desire for pregnancy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Benefits</strong> – Benefits of observation include preserved ovarian function and avoidance of surgical risk [<a href="#rid45">45-47</a>]. Observation over time also allows other benign ovarian cysts that could be confused for an endometrioma, such as hemorrhagic cysts, to regress.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Risks</strong> – The risks of observation include lack of histologic diagnosis, inability to exclude malignancy, and potential for disease progression.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach</strong> – For endometriomas that are being observed, a typical management plan involves physical examination and ultrasound every six months for one to two years, followed by annual examination and ultrasound if the adnexal mass has remained unchanged in size and clinical characteristics. Patients can be managed for many years using this conservative approach. Benefits include maintenance of ovarian reserve and avoidance of surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for change in approach</strong> – Onset of new symptoms or increasing cyst volume (the authors use cyst size &gt;5 cm) or complexity on imaging should prompt closer follow-up (ie, repeat pelvic ultrasound in 3 rather than 6 or 12 months). Two consecutive scans demonstrating clinically meaningful increased cyst volume or change in complexity of the cyst, or development of significant symptoms, should prompt surgical intervention. (See  <a class="medical medical_review" href="/z/d/html/83704.html" rel="external">"Approach to the patient with an adnexal mass", section on 'When to stop surveillance or proceed with surgery'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunct medical therapy</strong> – Hormonal therapy generally has no significant impact on endometrioma volume and is not indicated specifically for management of endometriomas. However, <a class="drug drug_general" data-topicid="17068" href="/z/d/drug information/17068.html" rel="external">dienogest</a> 2 mg per day has been associated with modest decreases in endometrioma cyst volume [<a href="#rid48">48-50</a>]. Ovulation suppression with hormonal therapy is beneficial in managing dysmenorrhea and may be useful in managing chronic pain symptoms associated with endometriosis [<a href="#rid48">48,49</a>].</p><p></p><p class="headingAnchor" id="H881755690"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>Surgical resection with either cystectomy or oophorectomy provides a definitive diagnosis, symptom relief, and exclusion of malignancy  (<a class="graphic graphic_diagnosticimage graphicRef100493" href="/z/d/graphic/100493.html" rel="external">image 2</a> and <a class="graphic graphic_algorithm graphicRef135005" href="/z/d/graphic/135005.html" rel="external">algorithm 1</a>). Risks of surgical resection include potential decreased ovarian reserve after resection and standard surgical risks [<a href="#rid45">45,51,52</a>]. (See  <a class="medical medical_review" href="/z/d/html/3304.html" rel="external">"Oophorectomy and ovarian cystectomy", section on 'Oophorectomy versus cystectomy'</a>.)</p><p class="headingAnchor" id="H3892912009"><span class="h3">Cystectomy (conservative surgery)</span><span class="headingEndMark"> — </span>Cystectomy involves removal of the endometrioma cyst while leaving the remainder of the normal ovary intact.</p><p class="headingAnchor" id="H772596315"><span class="h4">Our approach</span><span class="headingEndMark"> — </span>For those with known endometriosis, a symptomatic endometrioma, and/or an expanding suspected endometrioma, we suggest cystectomy, preferably by the laparoscopic route, rather than oophorectomy  (<a class="graphic graphic_algorithm graphicRef135005" href="/z/d/graphic/135005.html" rel="external">algorithm 1</a>). We inform patients that  conversion to laparotomy may be necessary in approximately 5 percent of attempted laparoscopic cystectomies for endometriomas, which is higher compared with other benign ovarian lesions [<a href="#rid53">53</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Cystectomy removes the endometrioma and provides an opportunity to resect other sites of endometriosis but leaves the normal ovary intact [<a href="#rid22">22</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We perform pelvic washing and frozen section evaluation in cases with suspicious or unusual morphology, either by ultrasound or direct visualization at the time of surgery. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After surgical resection, we recommend long-term treatment with an estrogen-progestin contraceptive to prevent endometrioma recurrence [<a href="#rid54">54</a>]. (See <a class="local">'Postoperative management'</a> below.)</p><p></p><p class="headingAnchor" id="H3084941536"><span class="h4">Cystectomy versus aspiration, fenestration, or sclerotherapy</span><span class="headingEndMark"> — </span>Cystectomy, preferably by laparoscopy, is preferred to other interventions for the treatment of pelvic pain or infertility because it is associated with a lower risk of endometrioma recurrence [<a href="#rid4">4,26</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aspiration</strong> – Cyst aspiration alone is ineffective with reported recurrence rates of 80 to 100 percent at six months of follow-up [<a href="#rid55">55-58</a>]. (See  <a class="medical medical_review" href="/z/d/html/3304.html" rel="external">"Oophorectomy and ovarian cystectomy", section on 'Aspiration and fenestration versus cystectomy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fenestration and ablation</strong> – Fenestration (removal of part of the cyst wall) and ablation (coagulation or laser vaporization of the inner side of the wall) is less effective than cystectomy, both in terms of improving fertility and reducing pain, but may have less impact on ovarian reserve [<a href="#rid26">26,59</a>]. (See  <a class="medical medical_review" href="/z/d/html/3304.html" rel="external">"Oophorectomy and ovarian cystectomy", section on 'Aspiration and fenestration versus cystectomy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyst sclerotherapy</strong> has also been attempted as a less-invasive alternative to cystectomy but has an unacceptably high recurrence rate without demonstrated benefit [<a href="#rid60">60</a>]. However, cyst sclerotherapy may be useful to reduce cyst size with the goal of improving access to follicles for aspiration during an IVF cycle [<a href="#rid61">61</a>]. (See <a class="local">'Cyst sclerotherapy'</a> below.)</p><p></p><p class="headingAnchor" id="H984511938"><span class="h4">Cystectomy technique</span><span class="headingEndMark"> — </span>Surgical issues to be considered at the time of endometrioma removal include the method of cyst removal, choice of hemostatic agent, and the extent of adjacent disease.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Method of cyst removal</strong> – Stripping the cyst wall instead of performing a circular excision around the cyst limits the number of normal ovarian follicles removed with the specimen [<a href="#rid62">62</a>]. A histologic analysis of endometriomas showed endometriosis of the inner cyst wall rarely penetrates more than 1.5 mm into the cyst capsule [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemostatic technique</strong> – Choice of hemostatic technique used on the ovary appears to impact postoperative anti-müllerian hormone (AMH) levels [<a href="#rid64">64-68</a>]. Two different meta-analyses reported hemostatic sealants and suture caused less reduction in AMH levels compared with bipolar electrosurgery [<a href="#rid69">69,70</a>]. We agree with the authors' suggestion to limit the use of bipolar electrocoagulation on the ovary. (See  <a class="medical medical_review" href="/z/d/html/4874.html" rel="external">"Instruments and devices used in laparoscopic surgery", section on 'Electrosurgery'</a>.)</p><p></p><p class="bulletIndent1">Use of <a class="drug drug_general" data-topicid="10083" href="/z/d/drug information/10083.html" rel="external">oxidized regenerated cellulose</a> can reduce surgical site bleeding and has been associated with reduced risk of cyst recurrence when used with both cyst drainage and cystectomy. In a trial including 200 patients with endometriomas that compared cystectomy and cyst drainage, each with and without application of oxidized cellulose, cyst recurrence rates were lower for both cellulose-treated groups over two years of follow-up [<a href="#rid71">71</a>]. AMH levels dropped in both cystectomy groups but remained unchanged in the group that underwent cyst drainage with cellulose insertion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjacent disease and/or adhesions</strong> – In our experience, endometrioma removal is often more difficult than the removal of other benign ovarian cysts because the contents of the endometrioma can chronically leak into the peritoneal cavity. This leakage causes dense scarring to structures adjacent to the cyst, making complete cystectomy more challenging. As cystectomy of endometriomas can be quite difficult, we discuss the potential need for oophorectomy with all individuals planning surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of other benign cysts</strong> – Many patients with endometriomas also have other benign ovarian cysts, such as hemorrhagic corpus luteum cysts or follicular cysts. While these adjacent cysts often increase the difficulty of endometrioma removal, they are left in situ when possible in an effort to retain as much normal ovarian tissue as possible.</p><p></p><p class="headingAnchor" id="H2533676099"><span class="h3">Oophorectomy with or without hysterectomy (definitive surgery)</span><span class="headingEndMark"> — </span>Oophorectomy involves removal of the ovary with the cyst intact and provides definitive surgical treatment. However, oophorectomy results in loss of ovarian function and bilateral oophorectomy in those under age 50 appears to increase the risks of all-cause mortality and cardiovascular disease. Decision to remove an ovary involves careful discussion on the risks of endometrioma recurrence and symptoms compared with risks and sequelae of loss of ovarian hormones  (<a class="graphic graphic_algorithm graphicRef135005" href="/z/d/graphic/135005.html" rel="external">algorithm 1</a>). At least one study has reported that salpingo-oophorectomy is more cost-effective than cystectomy for managing ovarian endometrioma in premenopausal patients [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/z/d/html/14198.html" rel="external">"Elective oophorectomy or ovarian conservation at the time of hysterectomy", section on 'Consequences of elective oophorectomy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Oophorectomy is mainly performed in patients who have recurrent cysts, have completed childbearing, are postmenopausal, or who have concerns for malignancy [<a href="#rid22">22</a>]. Unilateral oophorectomy resolves symptoms and reduces the risk of endometrioma recurrence. However, endometriomas or other cysts can still form in the contralateral ovary and, rarely, a retained ovarian remnant can cause pain symptoms. (See  <a class="medical medical_review" href="/z/d/html/3304.html" rel="external">"Oophorectomy and ovarian cystectomy", section on 'Ovarian remnant syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact on ovarian hormone production</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unilateral oophorectomy</strong> – The impact of unilateral oophorectomy on ovarian hormone production is unclear. Most studies that assess hormone production from the remaining ovary have looked at patients undergoing hysterectomy with and without unilateral oophorectomy. In studies of women having hysterectomy, the time interval to cessation of ovarian function is shorter for those who have unilateral oophorectomy in addition to hysterectomy, which raises concern that oophorectomy alone may reduce residual ovarian function [<a href="#rid72">72-75</a>]. Premature loss of ovarian function is associated with increased risk for cognitive impairment and cardiovascular events [<a href="#rid75">75-77</a>]. (See  <a class="medical medical_review" href="/z/d/html/14198.html" rel="external">"Elective oophorectomy or ovarian conservation at the time of hysterectomy", section on 'Consequences of elective oophorectomy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bilateral oophorectomy</strong> – Bilateral oophorectomy results in complete loss of ovarian function. Thus, this procedure is typically reserved for patients who have debilitating symptoms, have failed other therapies, and have completed childbearing [<a href="#rid3">3</a>]. Bilateral oophorectomy can be performed with or without concomitant hysterectomy and/or bilateral salpingectomy. (See  <a class="medical medical_review" href="/z/d/html/14198.html" rel="external">"Elective oophorectomy or ovarian conservation at the time of hysterectomy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Removal of entire adnexa (en bloc dissection)</strong> – If the patient has extensive unilateral pain and/or scarring around the ovary containing the endometrioma, the patient may benefit from removal of the entire adnexa (ie, en bloc dissection of the ovary, fallopian tube, and surrounding tissue). This dissection may necessitate opening the retroperitoneum, identifying and isolating the ureter, and ligating the infundibulopelvic ligament near the pelvic brim to avoid operating near the diseased tissue. This approach reduces the risk of retained ovarian tissue that could cause further symptoms. (See  <a class="medical medical_review" href="/z/d/html/17176.html" rel="external">"Ovarian remnant syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H3386055294"><span class="h3">Option for prophylactic salpingectomy</span><span class="headingEndMark"> — </span>Individuals who elect surgery with either ovarian cystectomy or oophorectomy have the option of concurrent salpingectomy (removal of the fallopian tubes) to reduce the risk of epithelial ovarian, fallopian tube, and peritoneal cancers. The balance of risks and benefits for this additional surgery depend on the patient's baseline risk of these cancers. Salpingectomy for cancer risk reduction is presented in detail in related content.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3250.html" rel="external">"Risk-reducing salpingo-oophorectomy in patients at high risk of epithelial ovarian and fallopian tube cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/91886.html" rel="external">"Opportunistic salpingectomy for ovarian, fallopian tube, and peritoneal carcinoma risk reduction"</a>.)</p><p></p><p class="headingAnchor" id="H2382903170"><span class="h2">Postoperative management</span></p><p class="headingAnchor" id="H1907111396"><span class="h3">Goals of treatment</span><span class="headingEndMark"> — </span>The use of postoperative medical therapy depends on the indication(s) for surgery and the patient's preferences regarding immediate attempt at pregnancy, use of medication, potential side effects of medication, and risk of cyst recurrence.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reduction of endometriosis-related pain recurrence</strong> – We, and other societies, advise postoperative medical suppressive therapy for most individuals treated surgically for endometriosis-related pain symptoms [<a href="#rid3">3,4,22</a>]. Individuals who desire immediate attempt of pregnancy are an exception. Discussion of treatment options and supporting data are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/16673.html" rel="external">"Endometriosis: Surgical management of pelvic pain", section on 'Postoperative care'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reduction of endometrioma recurrence</strong> – Postoperative medical treatment appears to reduce the risk of endometrioma recurrence if maintained for at least a year; the optimal drug regimen is not known and the available data are mixed [<a href="#rid78">78,79</a>]. Although the supporting data are of low quality, long-term suppression with combined estrogen-progestin contraceptives appears to be helpful and is of low overall risk. (See  <a class="medical medical_review" href="/z/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain", section on 'Estrogen-progestin contraceptives'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2022 network meta-analysis comparing medical treatment for a mean duration of at least 12 months with expectant management reported combined therapy with a gonadotropin-releasing hormone (GnRH) agonist and hormonal suppression was associated with lower risk of endometrioma recurrence compared with GnRH agonist alone or expectant management [<a href="#rid79">79</a>]. Hormonal suppression included oral contraceptive (OC) pills (multiple formulations), <a class="drug drug_general" data-topicid="17068" href="/z/d/drug information/17068.html" rel="external">dienogest</a>, and <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">levonorgestrel</a> intrauterine devices (<a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">LNG IUDs</a>). The risk of endometrioma recurrence was similar for treatment with GnRH agonist alone and expectant management (odds ratio 0.47, 95% CI 0.12-1.89). Shorter duration of treatment (three to six months) was not associated with reduced recurrence risk.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2021 network meta-analysis of six trials and 16 cohort studies reported a nonsignificant trend toward lower endometrioma recurrence rates with postoperative use of hormonal suppression, including OCs (continuous and cyclic), <a class="drug drug_general" data-topicid="17068" href="/z/d/drug information/17068.html" rel="external">dienogest</a>, <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">LNG IUDs</a>, and GnRH agonist therapy, compared with expectant management [<a href="#rid78">78</a>].</p><p></p><p class="headingAnchor" id="H3358833713"><span class="h3">Options for medical therapy</span><span class="headingEndMark"> — </span>Options for treatment of endometriosis-related pain include estrogen-progestin contraceptives, progestin-only therapies, GnRH agonists and antagonists, and <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">LNG IUDs</a>. If postoperative medical treatment is elected, estrogen-progestin contraceptives are often used because of general tolerability, availability, and ease of use in addition to data supporting reduced endometrioma recurrence rates with long-term (one year or greater) use. (See  <a class="medical medical_review" href="/z/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain", section on 'Medical treatment options'</a>.)</p><p class="headingAnchor" id="H3502455119"><span class="h4">Likely helpful</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral contraceptives (OCs)</strong> – Postoperative treatment with either a cyclic or continuous estrogen-progestin OC regimen is reasonable as treatment has been associated with reduced risk of endometrioma recurrence and reduction of endometriosis-related symptoms [<a href="#rid54">54,79-82</a>]. Continuous-dose OC regimens may provide additional benefit over cyclic ones [<a href="#rid83">83</a>]. Combined therapy with estrogen and progestin is preferred to progestin treatment alone; a study of endometrioma cells reported that cell growth was suppressed more by combination therapy with ethinyl <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">estradiol</a> and progestin than by progestins alone [<a href="#rid84">84</a>]. Estrogen-progestin contraceptive vaginal rings and patches have also been associated with reduction in endometriosis-related symptoms, but their impact on postoperative endometrioma recurrence has not been established [<a href="#rid85">85</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/16673.html" rel="external">"Endometriosis: Surgical management of pelvic pain", section on 'Postoperative medical therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain", section on 'Estrogen-progestin contraceptives'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="17068" href="/z/d/drug information/17068.html" rel="external">Dienogest</a> – Studies have reported postoperative dienogest reduced risk of endometrioma recurrence, was associated with resolution of recurrent cysts, and preserved AMH levels [<a href="#rid86">86-88</a>]. If used, treatment of six months or greater is advised as shorter duration of treatment has been associated with endometrioma recurrence risk similar to that of expectant management [<a href="#rid78">78</a>].</p><p></p><p class="headingAnchor" id="H3216834445"><span class="h4">Unclear benefit</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GnRH agonists and antagonists</strong> – Both GnRH agonist and antagonist therapy can be used for postoperative suppressive therapy for endometriosis and its related symptoms [<a href="#rid89">89-92</a>]; impact on endometrioma recurrence is less clear [<a href="#rid78">78</a>]. (See  <a class="medical medical_review" href="/z/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain", section on 'Gonadotropin-releasing hormone (GnRH) analogs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">Levonorgestrel</a><strong> intrauterine devices (</strong><a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">LNG IUDs</a><strong>)</strong> – While studies report reduced rates of dysmenorrhea in patients treated with LNG IUDs after surgical removal of endometriomas, the impact of LNG IUDs on endometrioma recurrence is less clear because of small study size, short duration of follow-up, and lack of placebo comparator [<a href="#rid93">93-95</a>]. Until further data are available from larger trials, we do not advise LNG IUD insertion for prevention of endometrioma recurrence and instead offer patients treatment with OCs as described in the first bullet. (See  <a class="medical medical_review" href="/z/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain", section on 'Alternate progestin treatment options'</a>.)</p><p></p><p class="headingAnchor" id="H845980321"><span class="h1">RISK OF ENDOMETRIOMA RECURRENCE</span></p><p class="headingAnchor" id="H614179253"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>Approximately 25 percent of patients who undergo surgical endometrioma removal will experience endometrioma recurrence [<a href="#rid96">96-98</a>]. In a study of 289 women who had undergone endometrioma resection, risk factors for endometrioma recurrence included removal of a cyst &gt;8 cm, younger age (&lt;25 years), and preoperative cyst rupture [<a href="#rid96">96</a>].</p><p>Repeat imaging is performed to reasonably exclude malignancy when recurrent endometrioma is suspected. (See  <a class="medical medical_review" href="/z/d/html/83704.html" rel="external">"Approach to the patient with an adnexal mass", section on 'Patients at increased risk of malignancy'</a>.)</p><p class="headingAnchor" id="H1814444484"><span class="h2">Concerns for repeat cystectomy</span><span class="headingEndMark"> — </span>Repeat cystectomy to remove a recurrent endometrioma may be more damaging to the ovary than initial cystectomy, although supporting data are limited to very small observational studies.</p><p class="bulletIndent1"><span class="glyph">●</span>One study of 11 women undergoing endometrioma cystectomy reported that the cyst wall specimen was thicker and contained more normal ovarian tissue in the recurrent endometrioma group as compared with the primary endometrioma resection group [<a href="#rid43">43</a>]. The recurrent endometrioma resection group also had a reduced antral follicle count (AFC) and ovarian volume on follow-up ultrasound study.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study that compared 18 women undergoing a second unilateral endometrioma resection with 18 women who underwent a primary resection only, the repeat resection group had decreased anti-müllerian hormone (AMH) levels, higher basal follicle-stimulating hormone (FSH) levels, and lower AFCs compared with the primary resection group [<a href="#rid99">99</a>]. Of note, the values for AMH, FSH, and AFC were not different between the groups after the primary surgery, which indicates the second surgery had an increased negative impact on ovarian reserve.</p><p></p><p class="headingAnchor" id="H1764340414"><span class="h1">LACK OF BENEFIT</span><span class="headingEndMark"> — </span>Medication management and sclerotherapy are not advised as they do not resolve endometriomas or treat associated symptoms.</p><p class="headingAnchor" id="H762339611"><span class="h2">Medical therapy</span><span class="headingEndMark"> — </span>While medical therapy is an effective treatment for pelvic pain caused by endometriosis, until recently it was thought that it has no benefits over observation for management of endometriomas [<a href="#rid1">1,3,100</a>]. However, three small observational studies assessing the impact of <a class="drug drug_general" data-topicid="17068" href="/z/d/drug information/17068.html" rel="external">dienogest</a> 2 mg daily reported a significant reduction in endometrioma volume (approximately 40 percent at six months and as much as 76 percent at 12 months) in addition to reductions in pelvic pain scores [<a href="#rid50">50,101,102</a>]. Although long-term data are lacking, dienogest may be considered for primary medical management in patients who prioritize avoiding surgery or for postoperative therapy to prevent recurrence. (See  <a class="medical medical_review" href="/z/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain"</a>.)</p><p class="headingAnchor" id="H2255243528"><span class="h2">Cyst sclerotherapy</span><span class="headingEndMark"> — </span>Cyst sclerotherapy has also been attempted as a less-invasive alternative to cystectomy. However, the endometrioma recurrence rate after sclerotherapy has been reported to be as high as 63 percent, without an improvement in clinical pregnancy rate when compared with traditional cystectomy or no treatment [<a href="#rid60">60</a>]. Sclerotherapy consists of injecting a sclerosing agent (ethanol, <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a>, or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>) into the cyst cavity and is thought to disrupt the cyst epithelial lining, which results in inflammation, fibrosis, and, ultimately, obliteration of the cyst. Comparing sclerotherapy with surgical resection have reported higher anti-müllerian hormone (AMH) levels following sclerotherapy but similar clinical pregnancy rates [<a href="#rid60">60,103</a>].</p><p class="headingAnchor" id="H1496917012"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109439.html" rel="external">"Society guideline links: Endometriosis"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/2174.html" rel="external">"Patient education: Endometriosis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Baseline evaluation</strong> – The baseline evaluation for individuals with suspected endometriomas includes imaging, typically with transvaginal pelvic ultrasound; assessment of risk of malignancy and presence of symptoms; and consideration of the patient's ovarian reserve and plan for future fertility. (See <a class="local">'Baseline evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance of ovarian reserve</strong> – Endometriomas themselves do not appear to diminish ovarian reserve but surgery to remove them is associated with reduced ovarian reserve as measured by anti-müllerian hormone (AMH) levels. While AMH level does not predict the probability of natural conception, it does predict live birth following in vitro fertilization (IVF). Therefore, the decision to proceed with ovarian surgery requires a careful discussion with the patient regarding the impact on ovarian function and plans for future fertility. (See <a class="local">'Consider importance of ovarian reserve'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment options</strong> –<strong> </strong>The main treatment options include active surveillance with serial imaging or surgical removal with cystectomy or oophorectomy  (<a class="graphic graphic_algorithm graphicRef135005" href="/z/d/graphic/135005.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Active surveillance</strong> –<strong> </strong>Active surveillance involves serial imaging to confirm findings consistent with an endometrioma and cyst stability. This approach preserves ovarian function and avoids surgical risk but cannot exclude malignancy. (See <a class="local">'Cystectomy (conservative surgery)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Surgical resection</strong> – Surgical resection with either cystectomy or oophorectomy provides a definitive diagnosis, relief of symptoms, and exclusion of malignancy. Risks of surgical resection include standard surgical risks and likely decreased ovarian reserve after resection (see <a class="local">'Surgery'</a> above). Some evidence suggests that surgical cyst drainage with placement of Surgicel may preserve ovarian function with recurrence rates similar to cystectomy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatments lacking benefit</strong> – Currently available medical therapy does not treat endometriomas and cyst sclerotherapy is associated with a high risk of recurrence. (See <a class="local">'Lack of benefit'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Select treatment approach</strong> – Management options include active surveillance with serial imaging or surgical resection  (<a class="graphic graphic_algorithm graphicRef135005" href="/z/d/graphic/135005.html" rel="external">algorithm 1</a>). (See <a class="local">'Select treatment approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Asymptomatic endometrioma</strong> – For individuals with asymptomatic cysts that have the imaging-based characteristics of an endometrioma and no other clinical risk factors for ovarian cancer, we suggest active surveillance rather than surgical excision (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We prefer active surveillance for those with a known diagnosis of endometriosis as excision may damage ovarian reserve. However, patients with symptoms related to the cyst (eg, pain), imaging findings suggestive of malignancy, or risk factors for ovarian cancer proceed with surgical excision of the lesion for histology diagnosis and treatment of pain. (See <a class="local">'Active surveillance'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endometrioma with symptoms</strong> – For patients with endometrioma-related symptoms (eg, pain, mass effect) who elect surgery with ovary conservation, we recommend cystectomy rather than fenestration and ablation (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Fenestration and ablation are less effective than cystectomy in reducing pain and improving fertility. We perform laparoscopic cystectomy with the stripping technique to preserve normal ovarian tissue. Aspiration is ineffective (see <a class="local">'Cystectomy (conservative surgery)'</a> above). Cyst drainage with Surgicel placement is a promising technique to preserve ovarian function with recurrence rates similar to cystectomy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Recurrent symptomatic endometrioma</strong> – Oophorectomy is reserved for patients with recurrent symptomatic endometriomas or for cysts with imaging findings concerning for malignancy. Bilateral oophorectomy, with or without concomitant hysterectomy, is reserved for individuals who have debilitating symptoms, have failed other therapies, and/or have completed childbearing. (See <a class="local">'Oophorectomy with or without hysterectomy (definitive surgery)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperative treatment</strong> – For premenopausal individuals who undergo surgical resection of endometrioma, we suggest postoperative use of estrogen-progestin oral contraceptive (OC) therapy rather than observation to reduce the risk of endometrioma recurrence (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Oral estrogen-progestin treatment has been associated with reduction of endometrioma recurrence and endometriosis-related symptoms. We typically prescribe combined OCs as efficacy of estrogen-progestin vaginal contraceptive rings and patches for endometrioma treatment has not been established. Continuous-dose regimens may provide additional benefit over cyclic therapy but both are reasonable; selection depends on patient preference. (See <a class="local">'Postoperative management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risks of endometrioma recurrence</strong> – Approximately 25 percent of women who undergo surgical endometrioma removal will experience endometrioma recurrence. Repeat cystectomy to remove a recurrent endometrioma may be more damaging to the ovary than initial cystectomy. (See <a class="local">'Risk of endometrioma recurrence'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Chapron C, Vercellini P, Barakat H, et al. Management of ovarian endometriomas. Hum Reprod Update 2002; 8:591.</a></li><li><a class="nounderline abstract_t">Abbott JA, Hawe J, Clayton RD, Garry R. The effects and effectiveness of laparoscopic excision of endometriosis: a prospective study with 2-5 year follow-up. Hum Reprod 2003; 18:1922.</a></li><li><a class="nounderline abstract_t">Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril 2014; 101:927.</a></li><li class="breakAll">Endometriosis Guideline of European Society of Human Reproduction and Embryology. 2022. Available at: https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Endometriosis-guideline (Accessed on February 09, 2022).</li><li><a class="nounderline abstract_t">Glanc P, Benacerraf B, Bourne T, et al. First International Consensus Report on Adnexal Masses: Management Recommendations. J Ultrasound Med 2017; 36:849.</a></li><li><a class="nounderline abstract_t">Nisenblat V, Bossuyt PM, Farquhar C, et al. Imaging modalities for the non-invasive diagnosis of endometriosis. Cochrane Database Syst Rev 2016; 2:CD009591.</a></li><li><a class="nounderline abstract_t">Friedrich L, Meyer R, Levin G. Management of adnexal mass: A comparison of five national guidelines. Eur J Obstet Gynecol Reprod Biol 2021; 265:80.</a></li><li><a class="nounderline abstract_t">Van Holsbeke C, Van Calster B, Guerriero S, et al. Endometriomas: their ultrasound characteristics. Ultrasound Obstet Gynecol 2010; 35:730.</a></li><li><a class="nounderline abstract_t">Guerriero S, Condous G, van den Bosch T, et al. Systematic approach to sonographic evaluation of the pelvis in women with suspected endometriosis, including terms, definitions and measurements: a consensus opinion from the International Deep Endometriosis Analysis (IDEA) group. Ultrasound Obstet Gynecol 2016; 48:318.</a></li><li><a class="nounderline abstract_t">Bazot M, Bharwani N, Huchon C, et al. European society of urogenital radiology (ESUR) guidelines: MR imaging of pelvic endometriosis. Eur Radiol 2017; 27:2765.</a></li><li><a class="nounderline abstract_t">Timmerman D, Van Calster B, Testa A, et al. Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group. Am J Obstet Gynecol 2016; 214:424.</a></li><li><a class="nounderline abstract_t">Van Calster B, Van Hoorde K, Valentin L, et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. BMJ 2014; 349:g5920.</a></li><li><a class="nounderline abstract_t">Sadowski EA, Paroder V, Patel-Lippmann K, et al. Indeterminate Adnexal Cysts at US: Prevalence and Characteristics of Ovarian Cancer. Radiology 2018; 287:1041.</a></li><li><a class="nounderline abstract_t">Anthoulakis C, Nikoloudis N. Pelvic MRI as the "gold standard" in the subsequent evaluation of ultrasound-indeterminate adnexal lesions: a systematic review. Gynecol Oncol 2014; 132:661.</a></li><li><a class="nounderline abstract_t">Haggerty AF, Hagemann AR, Chu C, et al. Correlation of pelvic magnetic resonance imaging diagnosis with pathology for indeterminate adnexal masses. Int J Gynecol Cancer 2014; 24:1215.</a></li><li><a class="nounderline abstract_t">Bernardin L, Dilks P, Liyanage S, et al. Effectiveness of semi-quantitative multiphase dynamic contrast-enhanced MRI as a predictor of malignancy in complex adnexal masses: radiological and pathological correlation. Eur Radiol 2012; 22:880.</a></li><li><a class="nounderline abstract_t">Thomassin-Naggara I, Daraï E, Cuenod CA, et al. Contribution of diffusion-weighted MR imaging for predicting benignity of complex adnexal masses. Eur Radiol 2009; 19:1544.</a></li><li><a class="nounderline abstract_t">Johnson NP, Hummelshoj L, World Endometriosis Society Montpellier Consortium. Consensus on current management of endometriosis. Hum Reprod 2013; 28:1552.</a></li><li><a class="nounderline abstract_t">Wentzensen N, Poole EM, Trabert B, et al. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. J Clin Oncol 2016; 34:2888.</a></li><li><a class="nounderline abstract_t">Mogensen JB, Kjær SK, Mellemkjær L, Jensen A. Endometriosis and risks for ovarian, endometrial and breast cancers: A nationwide cohort study. Gynecol Oncol 2016; 143:87.</a></li><li><a class="nounderline abstract_t">Saavalainen L, Lassus H, But A, et al. Risk of Gynecologic Cancer According to the Type of Endometriosis. Obstet Gynecol 2018; 131:1095.</a></li><li><a class="nounderline abstract_t">Practice bulletin no. 114: management of endometriosis. Obstet Gynecol 2010; 116:223.</a></li><li><a class="nounderline abstract_t">Magalhães JS, Jammal MP, Crispim PCA, et al. Role of biomarkers CA-125, CA-15.3 and CA-19.9 in the distinction between endometriomas and ovarian neoplasms. Biomarkers 2021; 26:268.</a></li><li><a class="nounderline abstract_t">Sarbazi F, Akbari E, Karimi A, et al. The Clinical Outcome of Laparoscopic Surgery for Endometriosis on Pain, Ovarian Reserve, and Cancer Antigen 125 (CA-125): A Cohort Study. Int J Fertil Steril 2021; 15:275.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists. ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol 2002; 100:1413.</a></li><li><a class="nounderline abstract_t">Hart RJ, Hickey M, Maouris P, Buckett W. Excisional surgery versus ablative surgery for ovarian endometriomata. Cochrane Database Syst Rev 2008; :CD004992.</a></li><li><a class="nounderline abstract_t">Hamdan M, Dunselman G, Li TC, Cheong Y. The impact of endometrioma on IVF/ICSI outcomes: a systematic review and meta-analysis. Hum Reprod Update 2015; 21:809.</a></li><li><a class="nounderline abstract_t">Demirdag E, Guler I, Selvi I, et al. Analysis of 2438 cycles for the impact of endometrioma and its surgery on the IVF outcomes. Eur J Obstet Gynecol Reprod Biol 2021; 263:233.</a></li><li><a class="nounderline abstract_t">Alshehre SM, Narice BF, Fenwick MA, Metwally M. The impact of endometrioma on in vitro fertilisation/intra-cytoplasmic injection IVF/ICSI reproductive outcomes: a systematic review and meta-analysis. Arch Gynecol Obstet 2021; 303:3.</a></li><li><a class="nounderline abstract_t">Loverro G, Carriero C, Rossi AC, et al. A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis. Eur J Obstet Gynecol Reprod Biol 2008; 136:194.</a></li><li><a class="nounderline abstract_t">Harrison RF, Barry-Kinsella C. Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study. Fertil Steril 2000; 74:24.</a></li><li><a class="nounderline abstract_t">Hwu YM, Wu FS, Li SH, et al. The impact of endometrioma and laparoscopic cystectomy on serum anti-Müllerian hormone levels. Reprod Biol Endocrinol 2011; 9:80.</a></li><li><a class="nounderline abstract_t">Leone Roberti Maggiore U, Scala C, Venturini PL, et al. Endometriotic ovarian cysts do not negatively affect the rate of spontaneous ovulation. Hum Reprod 2015; 30:299.</a></li><li><a class="nounderline abstract_t">Kasapoglu I, Ata B, Uyaniklar O, et al. Endometrioma-related reduction in ovarian reserve (ERROR): a prospective longitudinal study. Fertil Steril 2018; 110:122.</a></li><li><a class="nounderline abstract_t">Benschop L, Farquhar C, van der Poel N, Heineman MJ. Interventions for women with endometrioma prior to assisted reproductive technology. Cochrane Database Syst Rev 2010; :CD008571.</a></li><li><a class="nounderline abstract_t">Flyckt R, Soto E, Falcone T. Endometriomas and assisted reproductive technology. Semin Reprod Med 2013; 31:164.</a></li><li><a class="nounderline abstract_t">Karadağ C, Yoldemir T, Demircan Karadağ S, Turgut A. The effects of endometrioma size and bilaterality on ovarian reserve. J Obstet Gynaecol 2020; 40:531.</a></li><li><a class="nounderline abstract_t">Younis JS, Shapso N, Ben-Sira Y, et al. Endometrioma surgery-a systematic review and meta-analysis of the effect on antral follicle count and anti-Müllerian hormone. Am J Obstet Gynecol 2022; 226:33.</a></li><li><a class="nounderline abstract_t">Goodman L, Goldberg JM, Flyckt RL, et al. Effect of surgery on ovarian reserve in women with endometriomas, endometriosis. Am J Obstet Gynecol 2016.</a></li><li><a class="nounderline abstract_t">Muzii L, Di Tucci C, Di Feliciantonio M, et al. The effect of surgery for endometrioma on ovarian reserve evaluated by antral follicle count: a systematic review and meta-analysis. Hum Reprod 2014; 29:2190.</a></li><li><a class="nounderline abstract_t">Ozaki R, Kumakiri J, Tinelli A, et al. Evaluation of factors predicting diminished ovarian reserve before and after laparoscopic cystectomy for ovarian endometriomas: a prospective cohort study. J Ovarian Res 2016; 9:37.</a></li><li><a class="nounderline abstract_t">Goodman LR, Goldberg JM, Flyckt RL, et al. Effect of surgery on ovarian reserve in women with endometriomas, endometriosis and controls. Am J Obstet Gynecol 2016; 215:589.e1.</a></li><li><a class="nounderline abstract_t">Muzii L, Achilli C, Lecce F, et al. Second surgery for recurrent endometriomas is more harmful to healthy ovarian tissue and ovarian reserve than first surgery. Fertil Steril 2015; 103:738.</a></li><li><a class="nounderline abstract_t">Orlando MS, Cadish LA, Shepherd JP, et al. Salpingo-oophorectomy or surveillance for ovarian endometrioma in asymptomatic premenopausal women: a cost-effectiveness analysis. Am J Obstet Gynecol 2022; 227:311.e1.</a></li><li><a class="nounderline abstract_t">Raffi F, Metwally M, Amer S. The impact of excision of ovarian endometrioma on ovarian reserve: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012; 97:3146.</a></li><li><a class="nounderline abstract_t">Coccia ME, Rizzello F, Mariani G, et al. Ovarian surgery for bilateral endometriomas influences age at menopause. Hum Reprod 2011; 26:3000.</a></li><li><a class="nounderline abstract_t">Tanprasertkul C, Manusook S, Somprasit C, et al. Antimullerian hormone changes after laparoscopic ovarian cystectomy for endometrioma compared with the nonovarian conditions. Minim Invasive Surg 2014; 2014:654856.</a></li><li><a class="nounderline abstract_t">Xholli A, Filip G, Previtera F, Cagnacci A. Modification of endometrioma size during hormone therapy containing dienogest. Gynecol Endocrinol 2020; 36:545.</a></li><li><a class="nounderline abstract_t">Del Forno S, Mabrouk M, Arena A, et al. Dienogest or Norethindrone acetate for the treatment of ovarian endometriomas: Can we avoid surgery? Eur J Obstet Gynecol Reprod Biol 2019; 238:120.</a></li><li><a class="nounderline abstract_t">Uludag SZ, Demirtas E, Sahin Y, Aygen EM. Dienogest reduces endometrioma volume and endometriosis-related pain symptoms. J Obstet Gynaecol 2021; 41:1246.</a></li><li><a class="nounderline abstract_t">Somigliana E, Berlanda N, Benaglia L, et al. Surgical excision of endometriomas and ovarian reserve: a systematic review on serum antimüllerian hormone level modifications. Fertil Steril 2012; 98:1531.</a></li><li><a class="nounderline abstract_t">Uncu G, Kasapoglu I, Ozerkan K, et al. Prospective assessment of the impact of endometriomas and their removal on ovarian reserve and determinants of the rate of decline in ovarian reserve. Hum Reprod 2013; 28:2140.</a></li><li><a class="nounderline abstract_t">Orlando MS, Yao M, Chang OH, et al. Perioperative outcomes in a nationwide sample of patients undergoing surgical treatment of ovarian endometriomas. Fertil Steril 2022; 117:444.</a></li><li><a class="nounderline abstract_t">Seracchioli R, Mabrouk M, Frascà C, et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertil Steril 2010; 93:52.</a></li><li><a class="nounderline abstract_t">Saleh A, Tulandi T. Surgical management of ovarian endometrioma. Infertil Reprod Med Clin North Am 2000; 11:61.</a></li><li><a class="nounderline abstract_t">Vercellini P, Vendola N, Bocciolone L, et al. Laparoscopic aspiration of ovarian endometriomas. Effect with postoperative gonadotropin releasing hormone agonist treatment. J Reprod Med 1992; 37:577.</a></li><li><a class="nounderline abstract_t">Donnez J, Nisolle M, Gillerot S, et al. Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage. Fertil Steril 1994; 62:63.</a></li><li><a class="nounderline abstract_t">Marana R, Caruana P, Muzii L, et al. Operative laparoscopy for ovarian cysts. Excision vs. aspiration. J Reprod Med 1996; 41:435.</a></li><li><a class="nounderline abstract_t">Georgievska J, Sapunov S, Cekovska S, Vasilevska K. Effect of two laparoscopic techniques for treatment of ovarian endometrioma on ovarian reserve. Med Arch 2015; 69:88.</a></li><li><a class="nounderline abstract_t">Cohen A, Almog B, Tulandi T. Sclerotherapy in the management of ovarian endometrioma: systematic review and meta-analysis. Fertil Steril 2017; 108:117.</a></li><li><a class="nounderline abstract_t">Fisch JD, Sher G. Sclerotherapy with 5% tetracycline is a simple alternative to potentially complex surgical treatment of ovarian endometriomas before in vitro fertilization. Fertil Steril 2004; 82:437.</a></li><li><a class="nounderline abstract_t">Muzii L, Bellati F, Palaia I, et al. Laparoscopic stripping of endometriomas: a randomized trial on different surgical techniques. Part I: clinical results. Hum Reprod 2005; 20:1981.</a></li><li><a class="nounderline abstract_t">Muzii L, Bianchi A, Bellati F, et al. Histologic analysis of endometriomas: what the surgeon needs to know. Fertil Steril 2007; 87:362.</a></li><li><a class="nounderline abstract_t">Ferrero S, Venturini PL, Gillott DJ, et al. Hemostasis by bipolar coagulation versus suture after surgical stripping of bilateral ovarian endometriomas: a randomized controlled trial. J Minim Invasive Gynecol 2012; 19:722.</a></li><li><a class="nounderline abstract_t">Sönmezer M, Taşkın S, Gemici A, et al. Can ovarian damage be reduced using hemostatic matrix during laparoscopic endometrioma surgery? A prospective, randomized study. Arch Gynecol Obstet 2013; 287:1251.</a></li><li><a class="nounderline abstract_t">Kuroda M, Kuroda K, Arakawa A, et al. Histological assessment of impact of ovarian endometrioma and laparoscopic cystectomy on ovarian reserve. J Obstet Gynaecol Res 2012; 38:1187.</a></li><li><a class="nounderline abstract_t">Song T, Lee SH, Kim WY. Additional benefit of hemostatic sealant in preservation of ovarian reserve during laparoscopic ovarian cystectomy: a multi-center, randomized controlled trial. Hum Reprod 2014; 29:1659.</a></li><li><a class="nounderline abstract_t">Shi X, Saravelos SH, Zhou Q, et al. Prevention of postoperative adhesion reformation by intermittent intrauterine balloon therapy: a randomised controlled trial. BJOG 2019; 126:1259.</a></li><li><a class="nounderline abstract_t">Ata B, Turkgeldi E, Seyhan A, Urman B. Effect of hemostatic method on ovarian reserve following laparoscopic endometrioma excision; comparison of suture, hemostatic sealant, and bipolar dessication. A systematic review and meta-analysis. J Minim Invasive Gynecol 2015; 22:363.</a></li><li><a class="nounderline abstract_t">Peters A, Rindos NB, Lee T. Hemostasis During Ovarian Cystectomy: Systematic Review of the Impact of Suturing Versus Surgical Energy on Ovarian Function. J Minim Invasive Gynecol 2017; 24:235.</a></li><li><a class="nounderline abstract_t">Shaltout MF, Elsheikhah A, Maged AM, et al. A randomized controlled trial of a new technique for laparoscopic management of ovarian endometriosis preventing recurrence and keeping ovarian reserve. J Ovarian Res 2019; 12:66.</a></li><li><a class="nounderline abstract_t">Laughlin-Tommaso SK, Stewart EA, Grossardt BR, et al. Incidence, time trends, laterality, indications, and pathological findings of unilateral oophorectomy before menopause. Menopause 2014; 21:442.</a></li><li><a class="nounderline abstract_t">Read MD, Edey KA, Hapeshi J, Foy C. The age of ovarian failure following premenopausal hysterectomy with ovarian conservation. Menopause Int 2010; 16:56.</a></li><li><a class="nounderline abstract_t">Cooper GS, Thorp JM Jr. FSH levels in relation to hysterectomy and to unilateral oophorectomy. Obstet Gynecol 1999; 94:969.</a></li><li><a class="nounderline abstract_t">Rocca WA, Grossardt BR, Maraganore DM. The long-term effects of oophorectomy on cognitive and motor aging are age dependent. Neurodegener Dis 2008; 5:257.</a></li><li><a class="nounderline abstract_t">Zhou G, Liu J, Sun F, et al. Cognitive functioning in elderly women who underwent unilateral oophorectomy before menopause. Int J Neurosci 2011; 121:196.</a></li><li><a class="nounderline abstract_t">Roeters van Lennep JE, Heida KY, Bots ML, et al. Cardiovascular disease risk in women with premature ovarian insufficiency: A systematic review and meta-analysis. Eur J Prev Cardiol 2016; 23:178.</a></li><li><a class="nounderline abstract_t">Wattanayingcharoenchai R, Rattanasiri S, Charakorn C, et al. Postoperative hormonal treatment for prevention of endometrioma recurrence after ovarian cystectomy: a systematic review and network meta-analysis. BJOG 2021; 128:25.</a></li><li><a class="nounderline abstract_t">Chiu CC, Hsu TF, Jiang LY, et al. Maintenance Therapy for Preventing Endometrioma Recurrence after Endometriosis Resection Surgery - A Systematic Review and Network Meta-analysis. J Minim Invasive Gynecol 2022; 29:602.</a></li><li><a class="nounderline abstract_t">Vercellini P, DE Matteis S, Somigliana E, et al. Long-term adjuvant therapy for the prevention of postoperative endometrioma recurrence: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2013; 92:8.</a></li><li><a class="nounderline abstract_t">Seracchioli R, Mabrouk M, Manuzzi L, et al. Post-operative use of oral contraceptive pills for prevention of anatomical relapse or symptom-recurrence after conservative surgery for endometriosis. Hum Reprod 2009; 24:2729.</a></li><li><a class="nounderline abstract_t">Seo JW, Lee DY, Yoon BK, Choi D. The Efficacy of Postoperative Cyclic Oral Contraceptives after Gonadotropin-Releasing Hormone Agonist Therapy to Prevent Endometrioma Recurrence in Adolescents. J Pediatr Adolesc Gynecol 2017; 30:223.</a></li><li><a class="nounderline abstract_t">Muzii L, Di Tucci C, Achilli C, et al. Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian endometriomas: a systematic review and metaanalysis. Am J Obstet Gynecol 2016; 214:203.</a></li><li><a class="nounderline abstract_t">Bono Y, Kyo S, Kiyono T, et al. Concurrent estrogen action was essential for maximal progestin effect in oral contraceptives. Fertil Steril 2014; 101:1337.</a></li><li><a class="nounderline abstract_t">Vercellini P, Barbara G, Somigliana E, et al. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril 2010; 93:2150.</a></li><li><a class="nounderline abstract_t">Koshiba A, Mori T, Okimura H, et al. Dienogest therapy during the early stages of recurrence of endometrioma might be an alternative therapeutic option to avoid repeat surgeries. J Obstet Gynaecol Res 2018; 44:1970.</a></li><li><a class="nounderline abstract_t">Zakhari A, Edwards D, Ryu M, et al. Dienogest and the Risk of Endometriosis Recurrence Following Surgery: A Systematic Review and Meta-analysis. J Minim Invasive Gynecol 2020; 27:1503.</a></li><li><a class="nounderline abstract_t">Muraoka A, Osuka S, Yabuki A, et al. Impact of perioperative use of GnRH agonist or dienogest on ovarian reserve after cystectomy for endometriomas: a randomized controlled trial. Reprod Biol Endocrinol 2021; 19:179.</a></li><li><a class="nounderline abstract_t">Chen I, Veth VB, Choudhry AJ, et al. Pre- and postsurgical medical therapy for endometriosis surgery. Cochrane Database Syst Rev 2020; 11:CD003678.</a></li><li><a class="nounderline abstract_t">Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev 2010; :CD008475.</a></li><li><a class="nounderline abstract_t">Taylor HS, Giudice LC, Lessey BA, et al. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. N Engl J Med 2017; 377:28.</a></li><li><a class="nounderline abstract_t">Agarwal SK, Soliman AM, Pokrzywinski RM, et al. Clinically Meaningful Reduction in Dyspareunia Is Associated With Significant Improvements in Health-Related Quality of Life Among Women With Moderate to Severe Pain Associated With Endometriosis: A Pooled Analysis of Two Phase III Trials of Elagolix. J Sex Med 2020; 17:2427.</a></li><li><a class="nounderline abstract_t">Abou-Setta AM, Al-Inany HG, Farquhar CM. Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery. Cochrane Database Syst Rev 2006; :CD005072.</a></li><li><a class="nounderline abstract_t">Cho S, Jung JA, Lee Y, et al. Postoperative levonorgestrel-releasing intrauterine system versus oral contraceptives after gonadotropin-releasing hormone agonist treatment for preventing endometrioma recurrence. Acta Obstet Gynecol Scand 2014; 93:38.</a></li><li><a class="nounderline abstract_t">Chen YJ, Hsu TF, Huang BS, et al. Postoperative maintenance levonorgestrel-releasing intrauterine system and endometrioma recurrence: a randomized controlled study. Am J Obstet Gynecol 2017.</a></li><li><a class="nounderline abstract_t">Maul LV, Morrision JE, Schollmeyer T, et al. Surgical therapy of ovarian endometrioma: recurrence and pregnancy rates. JSLS 2014; 18.</a></li><li><a class="nounderline abstract_t">Guzel AI, Topcu HO, Ekilinc S, et al. Recurrence factors in women underwent laparoscopic surgery for endometrioma. Minerva Chir 2014; 69:277.</a></li><li><a class="nounderline abstract_t">Haraguchi H, Koga K, Takamura M, et al. Development of ovarian cancer after excision of endometrioma. Fertil Steril 2016; 106:1432.</a></li><li><a class="nounderline abstract_t">Ferrero S, Scala C, Racca A, et al. Second surgery for recurrent unilateral endometriomas and impact on ovarian reserve: a case-control study. Fertil Steril 2015; 103:1236.</a></li><li><a class="nounderline abstract_t">Alborzi S, Zarei A, Alborzi S, Alborzi M. Management of ovarian endometrioma. Clin Obstet Gynecol 2006; 49:480.</a></li><li><a class="nounderline abstract_t">Muzii L, Galati G, Di Tucci C, et al. Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain. Gynecol Endocrinol 2020; 36:81.</a></li><li><a class="nounderline abstract_t">Vignali M, Belloni GM, Pietropaolo G, et al. Effect of Dienogest therapy on the size of the endometrioma. Gynecol Endocrinol 2020; 36:723.</a></li><li><a class="nounderline abstract_t">Koo JH, Lee I, Han K, et al. Comparison of the therapeutic efficacy and ovarian reserve between catheter-directed sclerotherapy and surgical excision for ovarian endometrioma. Eur Radiol 2021; 31:543.</a></li></ol></div><div id="topicVersionRevision">Topic 3282 Version 42.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12498427" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Management of ovarian endometriomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12923150" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The effects and effectiveness of laparoscopic excision of endometriosis: a prospective study with 2-5 year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24630080" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Treatment of pelvic pain associated with endometriosis: a committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24630080" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Treatment of pelvic pain associated with endometriosis: a committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28266033" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : First International Consensus Report on Adnexal Masses: Management Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26919512" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Imaging modalities for the non-invasive diagnosis of endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34474226" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Management of adnexal mass: A comparison of five national guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20503240" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Endometriomas: their ultrasound characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27349699" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Systematic approach to sonographic evaluation of the pelvis in women with suspected endometriosis, including terms, definitions and measurements: a consensus opinion from the International Deep Endometriosis Analysis (IDEA) group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27921160" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : European society of urogenital radiology (ESUR) guidelines: MR imaging of pelvic endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26800772" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25320247" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29480762" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Indeterminate Adnexal Cysts at US: Prevalence and Characteristics of Ovarian Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24183731" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pelvic MRI as the "gold standard" in the subsequent evaluation of ultrasound-indeterminate adnexal lesions: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25153677" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Correlation of pelvic magnetic resonance imaging diagnosis with pathology for indeterminate adnexal masses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22095438" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effectiveness of semi-quantitative multiphase dynamic contrast-enhanced MRI as a predictor of malignancy in complex adnexal masses: radiological and pathological correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19214523" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Contribution of diffusion-weighted MR imaging for predicting benignity of complex adnexal masses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23528916" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Consensus on current management of endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27325851" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27430396" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Endometriosis and risks for ovarian, endometrial and breast cancers: A nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29742675" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Risk of Gynecologic Cancer According to the Type of Endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20567196" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Practice bulletin no. 114: management of endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33554683" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Role of biomarkers CA-125, CA-15.3 and CA-19.9 in the distinction between endometriomas and ovarian neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34913296" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The Clinical Outcome of Laparoscopic Surgery for Endometriosis on Pain, Ovarian Reserve, and Cancer Antigen 125 (CA-125): A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12468197" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18425908" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Excisional surgery versus ablative surgery for ovarian endometriomata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26168799" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The impact of endometrioma on IVF/ICSI outcomes: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34242932" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Analysis of 2438 cycles for the impact of endometrioma and its surgery on the IVF outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32979078" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The impact of endometrioma on in vitro fertilisation/intra-cytoplasmic injection IVF/ICSI reproductive outcomes: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17178185" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10899492" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21651823" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The impact of endometrioma and laparoscopic cystectomy on serum anti-Müllerian hormone levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25432923" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Endometriotic ovarian cysts do not negatively affect the rate of spontaneous ovulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29935810" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Endometrioma-related reduction in ovarian reserve (ERROR): a prospective longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21069706" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Interventions for women with endometrioma prior to assisted reproductive technology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23446864" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Endometriomas and assisted reproductive technology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31460808" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The effects of endometrioma size and bilaterality on ovarian reserve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34265271" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Endometrioma surgery-a systematic review and meta-analysis of the effect on antral follicle count and anti-Müllerian hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effect of surgery on ovarian reserve in women with endometriomas, endometriosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25085800" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The effect of surgery for endometrioma on ovarian reserve evaluated by antral follicle count: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27329142" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Evaluation of factors predicting diminished ovarian reserve before and after laparoscopic cystectomy for ovarian endometriomas: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27242204" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effect of surgery on ovarian reserve in women with endometriomas, endometriosis and controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25577464" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Second surgery for recurrent endometriomas is more harmful to healthy ovarian tissue and ovarian reserve than first surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35490792" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Salpingo-oophorectomy or surveillance for ovarian endometrioma in asymptomatic premenopausal women: a cost-effectiveness analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22723324" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The impact of excision of ovarian endometrioma on ovarian reserve: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21868401" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Ovarian surgery for bilateral endometriomas influences age at menopause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25580291" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Antimullerian hormone changes after laparoscopic ovarian cystectomy for endometrioma compared with the nonovarian conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31842632" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Modification of endometrioma size during hormone therapy containing dienogest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31132690" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Dienogest or Norethindrone acetate for the treatment of ovarian endometriomas: Can we avoid surgery?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33629621" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Dienogest reduces endometrioma volume and endometriosis-related pain symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22975114" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Surgical excision of endometriomas and ovarian reserve: a systematic review on serum antimüllerian hormone level modifications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23624580" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Prospective assessment of the impact of endometriomas and their removal on ovarian reserve and determinants of the rate of decline in ovarian reserve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34802687" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Perioperative outcomes in a nationwide sample of patients undergoing surgical treatment of ovarian endometriomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18973896" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Surgical management of ovarian endometrioma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1387905" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Laparoscopic aspiration of ovarian endometriomas. Effect with postoperative gonadotropin releasing hormone agonist treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8005305" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8799921" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Operative laparoscopy for ovarian cysts. Excision vs. aspiration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26005255" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effect of two laparoscopic techniques for treatment of ovarian endometrioma on ovarian reserve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28579409" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Sclerotherapy in the management of ovarian endometrioma: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15302295" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Sclerotherapy with 5% tetracycline is a simple alternative to potentially complex surgical treatment of ovarian endometriomas before in vitro fertilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15802314" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Laparoscopic stripping of endometriomas: a randomized trial on different surgical techniques. Part I: clinical results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17094980" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Histologic analysis of endometriomas: what the surgeon needs to know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23084676" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Hemostasis by bipolar coagulation versus suture after surgical stripping of bilateral ovarian endometriomas: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23291972" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Can ovarian damage be reduced using hemostatic matrix during laparoscopic endometrioma surgery? A prospective, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22540675" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Histological assessment of impact of ovarian endometrioma and laparoscopic cystectomy on ovarian reserve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24903197" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Additional benefit of hemostatic sealant in preservation of ovarian reserve during laparoscopic ovarian cystectomy: a multi-center, randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31207009" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Prevention of postoperative adhesion reformation by intermittent intrauterine balloon therapy: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25573183" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effect of hemostatic method on ovarian reserve following laparoscopic endometrioma excision; comparison of suture, hemostatic sealant, and bipolar dessication. A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28011097" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Hemostasis During Ovarian Cystectomy: Systematic Review of the Impact of Suturing Versus Surgical Energy on Ovarian Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31325962" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A randomized controlled trial of a new technique for laparoscopic management of ovarian endometriosis preventing recurrence and keeping ovarian reserve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24067261" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Incidence, time trends, laterality, indications, and pathological findings of unilateral oophorectomy before menopause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20729494" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The age of ovarian failure following premenopausal hysterectomy with ovarian conservation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10576184" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : FSH levels in relation to hysterectomy and to unilateral oophorectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18322406" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The long-term effects of oophorectomy on cognitive and motor aging are age dependent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21198412" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Cognitive functioning in elderly women who underwent unilateral oophorectomy before menopause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25331207" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Cardiovascular disease risk in women with premature ovarian insufficiency: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32558987" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Postoperative hormonal treatment for prevention of endometrioma recurrence after ovarian cystectomy: a systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35123042" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Maintenance Therapy for Preventing Endometrioma Recurrence after Endometriosis Resection Surgery - A Systematic Review and Network Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22646295" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Long-term adjuvant therapy for the prevention of postoperative endometrioma recurrence: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19625310" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Post-operative use of oral contraceptive pills for prevention of anatomical relapse or symptom-recurrence after conservative surgery for endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27744096" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The Efficacy of Postoperative Cyclic Oral Contraceptives after Gonadotropin-Releasing Hormone Agonist Therapy to Prevent Endometrioma Recurrence in Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26364832" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian endometriomas: a systematic review and metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24656887" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Concurrent estrogen action was essential for maximal progestin effect in oral contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19328469" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29992672" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Dienogest therapy during the early stages of recurrence of endometrioma might be an alternative therapeutic option to avoid repeat surgeries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32428571" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Dienogest and the Risk of Endometriosis Recurrence Following Surgery: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34872568" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Impact of perioperative use of GnRH agonist or dienogest on ovarian reserve after cystectomy for endometriomas: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33206374" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Pre- and postsurgical medical therapy for endometriosis surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21154398" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Gonadotrophin-releasing hormone analogues for pain associated with endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28525302" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32928659" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Clinically Meaningful Reduction in Dyspareunia Is Associated With Significant Improvements in Health-Related Quality of Life Among Women With Moderate to Severe Pain Associated With Endometriosis: A Pooled Analysis of Two Phase III Trials of Elagolix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17054236" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24605384" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Postoperative levonorgestrel-releasing intrauterine system versus oral contraceptives after gonadotropin-releasing hormone agonist treatment for preventing endometrioma recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28209488" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Postoperative maintenance levonorgestrel-releasing intrauterine system and endometrioma recurrence: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25392619" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Surgical therapy of ovarian endometrioma: recurrence and pregnancy rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25267018" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Recurrence factors in women underwent laparoscopic surgery for endometrioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27543889" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Development of ovarian cancer after excision of endometrioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25681854" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Second surgery for recurrent unilateral endometriomas and impact on ovarian reserve: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16885655" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Management of ovarian endometrioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31304853" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32065005" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Effect of Dienogest therapy on the size of the endometrioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32770376" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Comparison of the therapeutic efficacy and ovarian reserve between catheter-directed sclerotherapy and surgical excision for ovarian endometrioma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
